Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-04-19
2011-04-19
Duffy, Patricia A (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S139100, C424S165100, C424S184100, C435S069700, C435S252300, C435S320100, C536S023700, C530S300000
Reexamination Certificate
active
07927607
ABSTRACT:
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof fromS. agalactiae, and methods for isolating such antigens and specific uses thereof.
REFERENCES:
patent: 7098182 (2006-08-01), Le Page et al.
patent: 7378234 (2008-05-01), Buschle et al.
patent: WO 02/059148 (2002-08-01), None
Brodeur et al., “Identification of group B streptococcal Sip protein, which elicites cross-protective immunity,”Infection and Immunity, 68:5610-5618, 2000.
Accession No. ABP28545, 2002.
Accession No. ADV88412, 2005.
Ellis, “New Technologies for Making Vaccines,”Vaccines, WB Saunders Co., pp. 568-575, 1988.
Etz et al., “Identification of in vivo expressed vaccine candidate antigens fromStaphylococcus aureus,”Proc. Natl. Acad. Sci. USA, 99:6573-6578, 2002.
Glaser et al., “Genome sequence ofStreptococcus agalactia, a pathogen causing invasive neonatal disease,”Molecular Microbiology, 45:1499-1513, 2002.
Henics et al., “Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens,”Biotechniques, 35:196-200,202,20, 2003.
Hughes et al., “Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphate fusions,”FEMS Microbiology Letters, 222:263-271, 2003.
Klade, “Proteomics approaches towards antigen discovery in vaccine development,”Current Opinion in Molecular Therapeutics, 4:216-224, 2002.
Larsson et al., “Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine,”Vaccine, 17:454-458, 1999.
Michel et al., “Cloned alpha and beta C-protein antigens of group B Streptococci elicit protective immunity,”Infection and Immunity, 59:2023-2028, 1991.
Moyo et al., “The putative R1 protein of streptococcus agalactiae as serotype marker and target of protective antibodies,”APMIS, 109:842-848, 2001.
Office Action, mail date Dec. 13, 2006.
Office Action, mail date Aug. 9, 2007.
Stalhammar-Carlemalm et al., “Protein Rib: A Novel Group B Streptococcal Cell Surface Protein that Confers Protective Immunity and Is Expressed by Most Strains Causing Invasive Infections,”J. Exp. Med., 177: 1593-1603, 1993.
Tettelin et al., “Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae,”Proc. Natl. Acad. Sci. USA, 99:12391-12396, 2002.
“Streptococcus agalactiae2603V/R section 8 of 100 of the complete genome,” NCBI Nucleotide Database, Accession No. AE014198, 2002.
“Streptococcus agalactiaeNEM316 complete genome, segment 2,” NCBI Nucleotide Database, Accession No. AL766844, 2002.
Hanner Markus
Horky Markus
Kallenda Sabine
Meinke Andreas
Nagy Eszter
Baskar Padma V
Duffy Patricia A
Fulbright & Jaworski LLP
Intercell AG
LandOfFree
S. agalactiae antigens I and II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S. agalactiae antigens I and II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S. agalactiae antigens I and II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672329